FDA On Personalized Medicine: Don’t Skimp On Diagnostic Quality Development
Executive Summary
A Center for Devices and Radiological Health representative tells a conference on drug/diagnostic co-development that it doesn’t matter how well designed a study for a therapeutic agent is if the accompanying biomarker-targeted test is not reliable and uniformly implemented.
You may also be interested in...
Teva’s Synribo: Salvage Therapy, But Not Personalized Medicine
Omacetaxine finds new life as a salvage treatment in chronic myeloid leukemia after failing to pass FDA muster for targeted therapy in patients with a particular genetic mutation. FDA allowed Teva to pool data from two open-label studies to secure approval in a third-line setting.
Enrichment Guidance To Prod Sponsors Toward Prospective Patient Stratification
The sensitivity and specificity of the target identification could determine size of the off-target population, CDER senior statistical advisor Robert O’Neill says at DIA/FDA meeting on revitalizing R&D.
Can Erbitux Make Inroads In First-line Colon Cancer With Approved Companion Dx In Tow?
Erbitux wins FDA approval for first-line metastatic colorectal cancer negative for KRAS mutations detected with a companion diagnostic specifically approved for the drug. In theory, earlier use could help shore up sales. But the drug faces a tough competitor in the dominant Avastin and new products are on the near horizon.